IP Library Granted Patent US 10,532,043
Granted Patent B2
US 10,532,043 · App. 16/541,626 · Granted Jan 14, 2020

Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Inventors: Gene H. Zaid (Sterling, KS); Thomas W. Burgoyne (Lake Zurich, IL)
Assignee: Ankh Life Sciences Limited
A61K31/437A61K31/11A61K31/12A61K31/4375A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,532,043
App. No.
16/541,626
Granted
Jan 14, 2020
Kind
B2
Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Claims (10)

1. A therapeutic composition comprising a quantity of a harmine component selected from the group consisting of harmine, and the esters, metal complexes, and pharmaceutically acceptable salts thereof, with a quantity of a isovanillin component selected from the group consisting of vanillin, isovanillin, and mixtures thereof, and the esters, metal complexes, and pharmaceutically acceptable salts of the foregoing, said composition in a dosage form selected from the group consisting of gels, suspensions, solids, tablets, pills, and capsules, said harmine component and said isovanillin component being selected and present in amounts to provide anti-cancer synergy for the composition.

2. The composition of claim 1 , said isovanillin component comprising isovanillin.

3. The composition of claim 1 , wherein said isovanillin component is present at a level greater than that of said harmine component.

4. The composition of claim 1 , the weight ratio of said isovanillin component to said harmine component ranging from about 0.5:1 to 15:1.

5. The composition of claim 1 , said isovanillin component being present of from about 25-95% by weight, and said harmine component being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

6. A method of making a therapeutic composition in accordance with claim 1 , comprising the steps of mixing together a quantity of said harmine component, and a quantity of said isovanillin component.

7. The method of claim 6 , said isovanillin component comprising isovanillin.

8. The method of claim 6 , wherein said isovanillin component is present at a level greater than that of said harmine component.

9. The method of claim 6 , the weight ratio of said isovanillin component to said harmine component ranging from about 0.5:1 to 15:1.

10. The method of claim 6 , said isovanillin component being present of from about 25-95% by weight, and said harmine component being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2019
From: IONS PHARMACEUTICAL S.A R.L.
To: ANKH LIFE SCIENCES LIMITED
Reel/Frame 050064/0991 →
Continuity (11)
Continuation 16213774 · Dec 7, 2018
Continuation 15826101 · Nov 29, 2017
Continuation 15337987 · Oct 28, 2016
Continuation In Part PCTUS2015055968 · Oct 16, 2015
Continuation In Part 14721011 · May 26, 2015
Continuation PCTIB2016000723 · Apr 20, 2016
Continuation In Part 14721011 · May 26, 2015
Provisional Application 62184051 · Jun 24, 2015
Provisional Application 62161090 · May 13, 2015
Provisional Application 62066686 · Oct 21, 2014
Related Publication 20190365724A1 · Dec 5, 2019